#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mantle cell lymphoma refractory Bulbospinal muscular atrophy congenital Cardiac amyloidosis Diffuse large B-cell lymphoma Hereditary optic atrophy Primary myelofibrosis Renal disorder PIK3CA-activated mutation Mantle cell lymphoma stage III Follicular lymphoma stage III Non-renal cell carcinoma of kidney Malignant oligodendroglioma Heavy menstrual bleeding Frostbite Philadelphia chromosome positive More trials…

    Learn about Rare Diseases

    Epidermolysis bullosa – Life with Disease Inclusion body myositis – Life with Disease X-linked lymphoproliferative syndrome – Diagnostics Rhabdoid tumour Idiopathic pulmonary fibrosis – Trials in Disease Hepatoblastoma – Treatment Alport’s syndrome – Basic Information Ocular melanoma – Diagnostics Hyperoxaluria Leukoencephalopathy – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    XYLOMETAZOLINE HYDROCHLORIDE Idarubicin Anifrolumab Avibactam Antithymocyte Immunoglobulin Magnesium Oxide, Light Dyp688 ATIGOTATUG Mbf-118 Ivabradine Hydrochloride CHLORMADINONE ACETATE ALXN1920 Av-Ec2023 Sot102 LIGUFALIMAB Lisdexamfetamine Dimesylate TX000045 Hepatitis B Surface Antigen ACT-1004-1239 GOLD SODIUM THIOSULFATE More therapies…

    Learn about Your Condition

    Renal cancer metastatic EGFR gene mutation Nodular melanoma Neurotrophic keratopathy Pancreatitis relapsing Head and neck cancer stage IV Spinal pain Lymphocytic lymphoma Rhabdomyosarcoma recurrent Diabetic nephropathy Haemorrhagic stroke Eye disorder Gastrointestinal disorder Demyelination Head and neck cancer stage III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Prostate cancer

  • Study of enzalutamide compared to bicalutamide and flutamide in first-line treatment for patients with metastatic prostate cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Flutamide
    • Bicalutamide
    • Enzalutamide
    Ireland
  • Study on the Effectiveness and Safety of Apalutamide and Stereotactic Radiotherapy for Patients with High-Risk Localized or Locally Advanced Prostate Cancer

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Apalutamide
    Slovakia
  • Study on High-Intensity Focused Ultrasound and Leuprorelin Acetate for Intermediate Risk Prostate Cancer Patients

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Leuprorelin Acetate
    France
Previous Page
1 … 15 16 17

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.


European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.

Numer nieprawidłowy!
Numer nieprawidłowy!